ProCE Banner Activity

Evolving Treatment Paradigms for Gynecologic Malignancies: Application for Current and Future Practice

Slideset Download
Download this slideset from an ASCO satellite symposium to learn how the experts currently manage patients with endometrial, ovarian, and cervical cancers.

Released: June 03, 2022

Expiration: June 02, 2023

No longer available for credit.
Begin Activity

Share

Faculty

Nicoletta Colombo

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Lesley Scott

Lesley Scott

Shannon N. Westin

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Eisai Inc.

GlaxoSmithKline

ImmunoGen, Inc.

Merck Sharp & Dohme Corp.

Faculty Disclosure

Primary Author

Nicoletta Colombo, MD, PhD

Associate Professor of Obsterics and Gynecology
European Institute of Oncology 
University of Milan-Bicocca
Milan, Italy  

Nicoletta Colombo, MD, PhD, has disclosed that she has received consulting fees from AstraZeneca, BIOCAD, Clovis Oncology, Eisai, GlaxoSmithKline, ImmunoGen, Mersana, MSD/Merck, Novartis, Pfizer, Pharmamar, Roche, Takeda, and Tesaro.

Lesley Scott,

David Scott Miller, MD, FACOG, FACS, has disclosed that he has received consulting fees from AbbVie, AstraZeneca, Eisai, EMD Serono, GlaxoSmithKline, Incyte, iTeos Belgium SA, Myriad Genetics, Novocure, Seagen, Tarveda, and Tesaro and funds for research support from Advenchen, Agenus, AKESOBIO Australia PTY, Eisai Europe Limited, EMD Serono, Karyopharm, Merck Sharp & Dohme, Novocure, and Tesaro.

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Shannon N. Westin, MD, MPH, has disclosed that she has received consulting fees from Agenus, AstraZeneca, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, Lilly, Merck, Mereo, Novartis, Pfizer, Roche/Genentech, and Zentalis and funds for research support from AstraZeneca, Bayer, Bio-Path, Clovis Oncology, Cotinga, GlaxoSmithKline, Mereo, Novartis, and Roche/Genentech.